News
ADCT
--
0.00%
--
ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA®
LAUSANNE, Switzerland, September 13, 2021--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced tha...
Business Wire · 5d ago
ADC Therapeutics Receives EU Orphan-Drug Designation for Zynlonta; Shares Rise
MT Newswires · 5d ago
ADC Therapeutics to Participate in Morgan Stanley's 19th Annual Global Healthcare Conference
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, annou...
Business Wire · 09/09 11:15
Morgan Stanley Maintains Overweight on ADC Therapeutics, Lowers Price Target to $47
Morgan Stanley maintains ADC Therapeutics (NYSE:ADCT) with a Overweight and lowers the price target from $51 to $47.
Benzinga · 09/07 12:10
Morgan Stanley Adjusts ADC Therapeutics PT to $47 From $51, Maintains Overweight Rating
MT Newswires · 09/07 10:22
Enveric Biosciences and Cellect Biotechnology among healthcare gainers; Forte Biosciences among losers
Gainers: Cellect Biotechnology (NASDAQ:APOP) +39%. NeuroOne Medical Technologies (NASDAQ:NMTC) +17%. Enveric Biosciences (NASDAQ:ENVB) +16%. Impel NeuroPharma (NASDAQ:IMPL) +12%. Progenity (NASDAQ:PROG) +10%. Losers: Forte Biosciences (NASDAQ:FBRX) -81%. E...
Seekingalpha · 09/03 14:55
Sector Update: Health Care
MT Newswires · 09/03 13:35
ADC Therapeutics' Chief Medical Officer Resigns; Replacment named
MT Newswires · 09/03 11:39
ADC Therapeutics Chief Medical Officer Is Leaving the Company
marketwatch.com · 09/03 11:33
ADC Therapeutics Announces Medical Leadership Transition
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, annou...
Business Wire · 09/03 11:15
ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty
Benzinga · 08/26 16:27
ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million
LAUSANNE, Switzerland, August 26, 2021--ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced it had ...
Business Wire · 08/26 11:15
ADC Therapeutics Signs an Up to $325 Million Financing Agreement with HealthCare Royalty
MT Newswires · 08/26 09:14
ADC Therapeutics Shares Climb After RBC Starts Coverage at Outperform
MT Newswires · 08/09 11:49
RBC Capital Initiates Coverage On ADC Therapeutics with Outperform Rating, Announces Price Target of $33
RBC Capital analyst Kennen MacKay initiates coverage on ADC Therapeutics (NYSE:ADCT) with a Outperform rating and announces Price Target of $33.
Benzinga · 08/09 10:16
RBC Initiates Coverage of ADC Therapeutics With Outperform Rating, Speculative Risk Qualifier, Sets Price Target at $33
MT Newswires · 08/09 09:04
Is ADC Therapeutics (NYSE:ADCT) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Simply Wall St. · 08/06 05:12
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Misses Revenue Estimates
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 16.67% and -34.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/03 12:45
Webull provides a variety of real-time ADCT stock news. You can receive the latest news about ADC Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.